Clinical trials: Adult Disease
Dry Eye Syndrome
Piiloset Trehalose Emulsion Eye Drop Study in Moderate or Severe Dry Eye
The study evaluates the safety, ocular tolerability and efficacy of emulsion eye drops with sacha inchi seed oil, trehalose and hyaluronic acid in the treatment of moderate or severe dry eye in adult patients.
- Trial name
- NCT03569202
- Testing
- Piiloset Trehalose Emulsion Eye Drops, Control Eye Drops
- Where
- Finland
- Volunteers
- 64 people
- Sponsor
- Kuopio University Hospital
Lymphoma, Adult T-Cell Leukemia/Lymphoma
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
Adult T-cell leukemia/lymphoma (ATLL) is a rare form of cancer found mostly among people from the Caribbean islands, Western Africa, Brazil, Iran, and Japan.
- Conditions
- Lymphoma, Adult T-Cell Leukemia/Lymphoma, Lymphatic Diseases
- Trial name
- NCT03264131
- Testing
- Brentuximab Vedotin, CHEP
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hidradenitis Suppurativa
Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa
This study evaluates the effect of hypertonic saline 23.4% injection in fistulas or sinus tracts in adult patients with hidradenitis suppurativa.
- Trial name
- NCT02805595
- Testing
- 23.4% Hypertonic saline
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Beth Israel Deaconess Medical Center
Sickle Cell Disease
Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease
This Phase 1/Phase 2 study will evaluate GMI-1070, a pan-selectin inhibitor, in adults with stable sickle cell disease. The study will assess safety, pharmacokinetics, and microvascular effects of intravenous GMI-1070 in the…
- Trial name
- NCT00911495
- Testing
- GMI-1070
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- GlycoMimetics Incorporated
Ulcerative Colitis
Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis
The primary objective of this study is to demonstrate the efficacy of tilpisertib (formerly GS-4875) compared with placebo control in achieving clinical remission per modified Mayo Clinic Score (MCS) in adults with moderately to…
- Trial name
- Falcon (NCT04130919)
- Testing
- Tilpisertib
- Where
- 49 sites in United States, Australia and 7 more
- Volunteers
- 19 people
- Sponsor
- Gilead Sciences
Marburg Virus Disease
cAd3-Marburg Vaccine in Healthy Adults
RV 507 was a Phase I, open-label study to examine the safety, tolerability and immunogenicity of an investigational Marburg vaccine given by intramuscular (IM) injection to healthy adults.
- Trial name
- NCT03475056
- Testing
- cAd3-Marburg vaccine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Attention Deficit Hyperactivity Disorder
An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.
The primary aim of this study is to assess whether naltrexone as a monotherapy is effective in treating Attention Deficit Hyperactivity Disorder (ADHD) in adults.
- Trial name
- NCT01873729
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
COVID-19
The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
Subjects who have documented exposure to SARS-CoV-2 (COVID-19) will receive 4 doses of PUL-042 Inhalation Solution or 4 doses of a placebo solution by inhalation over 10 days.
- Trial name
- NCT04313023
- Testing
- PUL-042 Inhalation Solution
- Where
- 15 sites in United States
- Volunteers
- 217 people
- Sponsor
- Pulmotect, Inc.
Type 2 Diabetes Mellitus
A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes
The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D).
- Trial name
- PRONTO-T2D (NCT03214380)
- Testing
- LY900014, Insulin Lispro, Insulin Glargine
- Where
- 141 sites in United States, Argentina and 14 more
- Volunteers
- 933 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
This is a study to understand efficacy and safety of investigational agent (PF-04937319) compared to approved agent (glimepiride) in patients with diabetes on metformin
- Trial name
- NCT01517373
- Testing
- PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg
- Where
- 53 sites in United States, Bulgaria and 5 more
- Volunteers
- 304 people
- Sponsor
- Pfizer
Obesity
Study to Evaluate ARD-101 in Adults With Obesity
The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in obese subjects with a body mass index (BMI) of 30-45 kg/m2.
- Trial name
- NCT05121441
- Testing
- ARD-101
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Aardvark Therapeutics, Inc.
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Ipilimumab and Local Radiation for Selected Solid Tumors
This pilot phase 1-2 trial studies the side effects and best of dose ipilimumab when given together with local radiation therapy and to see how well it works in treating patients with recurrent melanoma, non-Hodgkin lymphoma…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01769222
- Testing
- Ipilimumab, Radiation therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Stanford University
Hepatitis B, Chronic
Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B
The purpose of this study is to compare the effectiveness of entecavir plus tenofovir combination therapy with that of entecavir monotherapy. Safety will also be studied.
- Trial name
- NCT00410072
- Testing
- Entecavir, Entecavir + Tenofovir
- Where
- 68 sites in United States, Argentina and 11 more
- Volunteers
- 669 people
- Sponsor
- Bristol-Myers Squibb
Brain and Central Nervous System Tumors
Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00304031
- Testing
- Concurrent temozolomide, Concurrent radiation therapy, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle
- Where
- 351 sites in United States, Canada
- Volunteers
- 1,173 people
- Sponsor
- Radiation Therapy Oncology Group
Dengue
An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge
The investigational study drug, JNJ-64281802, is being developed for the prevention and treatment of dengue infection. This study is hypothesizing that the highest dose of the investigational study drug is superior to receiving a…
- Trial name
- NCT05048875
- Testing
- Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dermatitis, Atopic, Pruritus
A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis
The goal of this clinical trial is to evaluate ASN008 in people with itch caused by eczema. The main questions it aims to answer are: What is the efficacy and safety of ASN008? What is the impact of ASN008 on itch in patients…
- Trial name
- NCT05870865
- Testing
- ASN008, ASN008 Matching Vehicle
- Where
- 27 sites in United States
- Volunteers
- 144 people
- Sponsor
- Formation Bio, Inc.
Adult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
This phase II trial is to see if bevacizumab works in treating patients who have unresectable nonmetastatic liver cancer that has not spread to the main portal vein.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00055692
- Testing
- bevacizumab
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Caries, Dental, Cariostatic Agents
Reducing Bacteria That Cause Tooth Decay
The purpose of the study is to determine the effect of a two-step mouth rinsing procedure on reducing the germs (mutans Streptococci) that cause tooth decay.
- Trial name
- NCT03062605
- Testing
- Iodine (Betadine), NaOCL
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin, ifosfamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma
- Trial name
- NCT00470366
- Testing
- pegfilgrastim, cisplatin, ifosfamide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Dry Eye Syndromes
A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants
This study will evaluate the safety, tolerability and efficacy of IC265 compared to vehicle in participants with signs and symptoms dry eye disease.
- Trial name
- NCT05992922
- Testing
- IC265 Ophthalmic Solution 1%
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Iacta Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.